MIRA MIRA Pharmaceuticals, Inc.
Fundamentals / CIK 0001904286 / USDMIRA Pharmaceuticals, Inc. reported $7.27M in total assets and a net loss of $9.76M through December 31, 2025 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open MIRA in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025-- Dec 31, 2025
-
Operating Income FY 2025-- Operating profit
-
Net Income FY 2025-$9.76M GAAP bottom line
-
Diluted EPS FY 2025-$1.35 Split-adjusted
-
Free Cash Flow FY 2025-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$6.97M Total debt: --
Annual revenue and net income
4 fiscal years (2022 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Research & Development | $1.72M | $3.31M | $1.57M | $2.35M |
| Total Operating Expenses | $10.49M | $8.02M | $8.53M | $7.05M |
| Interest Expense | -- | -$166K | $3.46M | $10K |
| Net Income | -$10.44M | -$7.85M | -$11.98M | -$7.06M |
| Basic EPS | -$1.35 | -$0.51 | -$0.85 | -$0.53 |
| Diluted EPS | -$1.35 | -$0.51 | -$0.85 | -$0.53 |
| Basic Shares Outstanding | 23.7M | 15.4M | 13.9M | 13.2M |
| Diluted Shares Outstanding | -- | 15.4M | 13.9M | 13.2M |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Research & Development | $947K | $706K | $525K | $497K | $413K | $496K | $314K | $861K |
| Total Operating Expenses | $1.41M | $1.16M | $1.10M | $5.82M | $1.32M | $1.55M | $1.81M | $2.44M |
| Interest Expense | -- | -- | -- | -- | -- | -- | -$21K | -$38K |
| Net Income | -$1.42M | -$1.21M | -$1.15M | -$5.98M | -$1.14M | -$1.54M | -$1.78M | -$2.40M |
| Basic EPS | -- | -$0.03 | -$0.03 | -- | -$1.18 | -$0.09 | -$0.11 | -- |
| Diluted EPS | -$0.03 | -$0.03 | -$0.03 | -- | -$1.18 | -$0.09 | -$0.11 | -- |
| Basic Shares Outstanding | 42.0M | 42.0M | 41.9M | -- | 19.3M | 17.0M | 16.6M | -- |
| Diluted Shares Outstanding | -- | -- | -- | -- | 19.3M | 17.0M | 16.6M | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $6.35M | $2.83M | $4.60M | $351K |
| Short-Term Investments | $4.68M | -- | -- | -- |
| Cash & Short-Term Investments | $11.03M | $2.83M | $4.60M | $351K |
| Accounts Receivable, Net | -- | $5.0K | $5.0K | -- |
| Total Current Assets | $11.06M | $2.89M | $4.86M | $494K |
| Total Non-Current Assets | $35K | $35K | $74K | $364K |
| Total Assets | $11.09M | $2.92M | $4.93M | $858K |
| Accounts Payable | $129K | $723K | $539K | $789K |
| Other Current Liabilities | $573K | -- | -- | -- |
| Total Current Liabilities | $702K | $723K | $558K | $1.37M |
| Total Non-Current Liabilities | $0 | $0 | $0 | $84K |
| Total Liabilities | $702K | $723K | $558K | $1.45M |
| Total Debt (incl. Leases) | -- | -- | $5.1K | $84K |
| Common Stock | $4.2K | $1.7K | $1.5K | $6.7K |
| Retained Earnings | -$39.58M | -$29.14M | -$21.29M | -$9.30M |
| Total Stockholders' Equity | $10.39M | $2.20M | $4.37M | -$596K |
| Total Equity | $10.39M | $2.20M | $4.37M | -$596K |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $2.50M | $3.61M | $4.82M | $6.35M | $2.64M | $730K | $1.21M | $2.83M |
| Short-Term Investments | $4.47M | $4.50M | $4.59M | $4.68M | $4.89M | -- | -- | -- |
| Cash & Short-Term Investments | $6.97M | $8.11M | $9.41M | $11.03M | $7.54M | $730K | $1.21M | $2.83M |
| Accounts Receivable, Net | -- | -- | -- | -- | -- | -- | -- | $5.0K |
| Total Current Assets | $7.23M | $8.17M | $9.43M | $11.06M | $7.60M | $833K | $1.36M | $2.89M |
| Total Non-Current Assets | $35K | $35K | $35K | $35K | $35K | $35K | $35K | $35K |
| Total Assets | $7.27M | $8.20M | $9.46M | $11.09M | $7.63M | $868K | $1.40M | $2.92M |
| Accounts Payable | $232K | $41K | $34K | $129K | $84K | $298K | $101K | $723K |
| Other Current Liabilities | -- | -- | -- | $573K | -- | -- | -- | -- |
| Total Current Liabilities | $426K | $41K | $115K | $702K | $84K | $298K | $106K | $723K |
| Total Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $426K | $41K | $115K | $702K | $84K | $298K | $106K | $723K |
| Common Stock | $4.2K | $4.2K | $4.2K | $4.2K | $4.0K | $1.7K | $1.7K | $1.7K |
| Retained Earnings | -$43.36M | -$41.94M | -$40.73M | -$39.58M | -$33.60M | -$32.46M | -$30.92M | -$29.14M |
| Total Stockholders' Equity | $6.84M | $8.16M | $9.35M | $10.39M | $7.55M | $570K | $1.29M | $2.20M |
| Total Equity | $6.84M | $8.16M | $9.35M | $10.39M | $7.55M | $570K | $1.29M | $2.20M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Net Income | -$10.44M | -$7.85M | -$11.98M | -$7.06M |
| Stock-Based Compensation | $6.31M | $1.92M | $2.55M | $1.30M |
| Change in Receivables | -- | -- | -$12K | -- |
| Operating Cash Flow | -$4.66M | -$5.56M | -$4.53M | -$5.60M |
| Common Stock Issued | $7.01M | $3.61M | $7.70M | $2.90M |
| Financing Cash Flow | $8.18M | $3.79M | $8.78M | $3.15M |
| Net Change in Cash | $3.51M | -$1.77M | $4.25M | -$2.46M |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$1.42M | -$1.21M | -$1.15M | -$5.98M | -$1.14M | -$1.54M | -$1.78M | -$2.40M |
| Stock-Based Compensation | $102K | $22K | $108K | $4.56M | $391K | $490K | $875K | $547K |
| Operating Cash Flow | -$1.30M | -$1.21M | -$1.20M | -$1.14M | -$1.10M | -$800K | -$1.63M | -$1.81M |
| Common Stock Issued | -- | -- | -- | $3.84M | $2.82M | $345K | $3.4K | -- |
| Financing Cash Flow | $194K | $0 | -$331K | $4.84M | $3.01M | $324K | $3.4K | $493K |
| Net Change in Cash | -$1.10M | -$1.21M | -$1.53M | $3.71M | $1.91M | -$476K | -$1.63M | -$1.31M |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Return on Equity (ROE) | -100.5% | -357.0% | -273.9% | -- |
| Return on Assets (ROA) | -94.1% | -268.6% | -242.9% | -822.6% |
| Current Ratio | 15.75x | 3.99x | 8.70x | 0.36x |
| Quick Ratio | 15.71x | 3.92x | 8.26x | 0.26x |
| Debt to Equity | -- | -- | 0.00x | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -142.7% | -116.1% | -104.9% | -100.5% | -90.9% | -1362.6% | -611.9% | -357.0% |
| Return on Assets (ROA) | -134.4% | -115.6% | -103.6% | -94.1% | -89.9% | -894.3% | -565.5% | -268.6% |
| Current Ratio | 16.97x | 200.08x | 82.16x | 15.75x | 90.53x | 2.79x | 12.86x | 3.99x |
| Quick Ratio | 16.36x | 198.75x | 81.97x | 15.71x | 89.79x | 2.45x | 11.36x | 3.92x |